{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:46:58Z","timestamp":1786985218343,"version":"build-2736575974"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["IIRPG-2023-0000318"],"award-info":[{"award-number":["IIRPG-2023-0000318"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.bioorg.2025.108991","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T06:40:34Z","timestamp":1757918434000},"page":"108991","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Quinazoline-based fourth-generation EGFR tyrosine kinase inhibitors to overcome C797S-mediated resistance in non-small cell lung Cancer (NSCLC)"],"prefix":"10.1016","volume":"165","author":[{"given":"Bhatu R.","family":"Patil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kisan","family":"Pawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matin","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faizan","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandragouda R.","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrakant S.","family":"Gawli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanakya Nath","family":"Kundu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biswajit","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iqrar","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harun M.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.108991_bb0005","first-page":"3764","article-title":"Clinical advances in EGFR-TKI combination therapy for EGFR-mutated NSCLC: a narrative review, Transl","volume":"12","author":"Zhang","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108991_bb0010","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2016.00076","article-title":"Next-generation EGFR tyrosine kinase inhibitors for treating EGFR-mutant lung Cancer beyond first line","volume":"3","author":"Sullivan","year":"2017","journal-title":"Front. Med."},{"key":"10.1016\/j.bioorg.2025.108991_bb0015","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejmech.2017.05.027","article-title":"Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance","volume":"142","author":"Patel","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108991_bb0020","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.jtho.2022.01.007","article-title":"The challenges of third-generation EGFR tyrosine kinase inhibitors in the therapy of advanced NSCLC","volume":"17","author":"Wang","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bioorg.2025.108991_bb0025","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1021\/acs.jmedchem.1c00876","article-title":"Emerging approaches to overcome acquired drug resistance obstacles to Osimertinib in non-small-cell lung Cancer","volume":"65","author":"Shaikh","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108991_bb0030","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1039\/D4MD00384E","article-title":"Next-generation EGFR tyrosine kinase inhibitors to overcome C797S mutation in non-small cell lung cancer (2019\u20132024)","volume":"15","author":"Das","year":"2024","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108991_bb0035","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.2174\/1568026622666220801101706","article-title":"Next-generation Bruton's tyrosine kinase (BTK) inhibitors potentially targeting BTK C481S mutation- recent developments and perspectives","volume":"22","author":"Das","year":"2022","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108991_bb0040","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2025.108991_bb0045","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/14728222.2017.1272582","article-title":"Targeting the EGFR T790M mutation in non-small-cell lung cancer","volume":"21","author":"Normanno","year":"2017","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.bioorg.2025.108991_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/ijo.2021.5270","article-title":"Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer (review)","volume":"59","author":"He","year":"2021","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bioorg.2025.108991_bb0055","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.phrs.2017.01.003","article-title":"Targeting EGFR T790M mutation in NSCLC: from biology to evaluation and treatment","volume":"117","author":"Passaro","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2025.108991_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117140","article-title":"Catalytic Lysine745 targeting strategy in fourth-generation EGFR tyrosine kinase inhibitors to address C797S mutation resistance","volume":"283","author":"Patil","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108991_bb0065","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s11523-022-00878-x","article-title":"The difference in clinical outcomes between Osimertinib and Afatinib for first-line treatment in patients with advanced and recurrent EGFR-mutant non-small cell lung Cancer in Taiwan","volume":"17","author":"Huang","year":"2022","journal-title":"Target. Oncol."},{"key":"10.1016\/j.bioorg.2025.108991_bb0070","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s11523-022-00928-4","article-title":"Correction to: the difference in clinical outcomes between Osimertinib and Afatinib for first-line treatment in patients with advanced and recurrent EGFR-mutant non-small cell lung Cancer in Taiwan","volume":"18","author":"Huang","year":"2023","journal-title":"Target. Oncol."},{"key":"10.1016\/j.bioorg.2025.108991_bb0075","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.70036","article-title":"Orthoallosteric EGFR-TKIs: a new paradigm in NSCLC treatment strategy targeting the C797S mutation","volume":"86","author":"Ahmad","year":"2025","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.bioorg.2025.108991_bb0080","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1001\/jamaoncol.2018.2969","article-title":"Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M\u2013positive lung Cancer and acquired resistance to Osimertinib","volume":"4","author":"Oxnard","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.bioorg.2025.108991_bb0085","first-page":"988","article-title":"Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors from the natural origin: a recent perspective, anticancer. Agents","volume":"15","author":"Patel","year":"2015","journal-title":"Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108991_bb0090","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1158\/0008-5472.CAN-18-1281","article-title":"Novel third-generation EGFR tyrosine kinase inhibitors and strategies to overcome therapeutic resistance in lung cancer","volume":"79","author":"Murtuza","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108991_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102557","article-title":"Acquired resistance mechanisms to osimertinib: the constant battle","volume":"116","author":"Zalaquett","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bioorg.2025.108991_bb0100","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.3390\/cancers15205079","article-title":"New generations of tyrosine kinase inhibitors in treating NSCLC with oncogene addiction: strengths and limitations","volume":"15","author":"Attili","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2025.108991_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117178","article-title":"From challenges to solutions: a review of fourth-generation EGFR tyrosine kinase inhibitors to overcome the C797S triple mutation in non-small cell lung cancer","volume":"284","author":"Ahmad","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108991_bb0110","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2017.00113","article-title":"Third-generation tyrosine kinase inhibitors targeting epidermal growth factor receptor mutations in non-small cell lung Cancer","volume":"7","author":"Barnes","year":"2017","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2025.108991_bb0115","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.canlet.2019.05.044","article-title":"Clinical management of third-generation EGFR inhibitor-resistant patients with advanced non-small cell lung cancer: current status and future perspectives","volume":"459","author":"Zhang","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2025.108991_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117796","article-title":"Exploring the structural activity relationship of the Osimertinib: a covalent inhibitor of double mutant EGFRL858R\/T790M tyrosine kinase for the treatment of non-small cell lung Cancer (NSCLC)","volume":"109","author":"Patil","year":"2024","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108991_bb0125","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.drudis.2017.10.004","article-title":"Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors","volume":"23","author":"Singh","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bioorg.2025.108991_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118146","article-title":"A clinical review on third and fourth generation EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer","volume":"123","author":"Gawli","year":"2025","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108991_bb0135","doi-asserted-by":"crossref","first-page":"7634","DOI":"10.1002\/anie.201703389","article-title":"Discovery of EGF receptor inhibitors that are selective for the d746-750\/T790M\/C797S mutant through structure-based de novo design","volume":"56","author":"Park","year":"2017","journal-title":"Angew. Chemie - Int. Ed."},{"key":"10.1016\/j.bioorg.2025.108991_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104848","article-title":"Design, synthesis and evaluation of anti-proliferative activity of 2-aryl-4-aminoquinazoline derivatives as EGFR inhibitors","volume":"112","author":"Zhou","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108991_bb0145","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1158\/1078-0432.CCR-22-3901","article-title":"BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non\u2013Small Cell Lung Cancer","volume":"29","author":"Lim","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108991_bb0150","first-page":"220","article-title":"What the future holds: BBT-176, beyond third-generation EGFR tyrosine kinase inhibitors, Transl. Lung","volume":"13","author":"Laface","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108991_bb0155","doi-asserted-by":"crossref","first-page":"5461","DOI":"10.1158\/1538-7445.AM2022-5461","article-title":"Abstract 5461: H002: a wide spectrum, highly selective fourth-generation EGFR inhibitor overcoming resistance harboring C797S mutation in NSCLC","volume":"82","author":"Huang","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108991_bb0160","article-title":"Crystal structure of EGFR(L858R\/T790M\/C797S) in complex with CH7233163","author":"Kawauchi","year":"2020","journal-title":"Worldw. Protein Data Bank"},{"key":"10.1016\/j.bioorg.2025.108991_bb0165","doi-asserted-by":"crossref","first-page":"16307","DOI":"10.1021\/acsomega.0c02183","article-title":"Molecular dynamics analysis of binding sites of epidermal growth factor receptor kinase inhibitors","volume":"5","author":"Li","year":"2020","journal-title":"ACS Omega"},{"key":"10.1016\/j.bioorg.2025.108991_bb0170","doi-asserted-by":"crossref","first-page":"4870","DOI":"10.1080\/07391102.2023.2223663","article-title":"Computational identification of new TKI as potential noncovalent reversible EGFR L858R\/T790M inhibitors: VHTS, molecular docking, DFT study and molecular dynamic simulation","volume":"42","author":"Abdelmalek","year":"2024","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bioorg.2025.108991_bb0175","doi-asserted-by":"crossref","first-page":"4534","DOI":"10.1080\/07391102.2022.2068650","article-title":"Investigation of molecular mechanism leading to gefitinib and osimertinib resistance against EGFR tyrosine kinase: molecular dynamics and binding free energy calculation","volume":"41","author":"Singh","year":"2023","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bioorg.2025.108991_bb0180","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41698-021-00170-7","article-title":"Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity","volume":"5","author":"Yoshizawa","year":"2021","journal-title":"Npj Precis. Oncol."},{"key":"10.1016\/j.bioorg.2025.108991_bb0185","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1109\/TCBB.2020.2995569","article-title":"Correlated motions and dynamics in different domains of epidermal growth factor receptor with L858R and T790M mutations","volume":"19","author":"Qureshi","year":"2022","journal-title":"IEEE\/ACM Trans. Comput. Biol. Bioinforma."},{"key":"10.1016\/j.bioorg.2025.108991_bb0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0310802","article-title":"Nature's defense against emerging neurodegenerative threats: dynamic simulation, PCA, DCCM identified potential plant-based antiviral lead targeting Borna disease virus nucleoprotein","volume":"19","author":"Siddiquee","year":"2024","journal-title":"PloS One"},{"key":"10.1016\/j.bioorg.2025.108991_bb0195","article-title":"Structural insights into conformational stability and binding of thiazolo-[2,3-b] quinazolinone derivatives with EGFR-TKD and in-vitro study, Saudi","volume":"29","author":"Ahmad Mir","year":"2022","journal-title":"Aust. J. Biol. Sci."},{"key":"10.1016\/j.bioorg.2025.108991_bb0200","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1080\/07391102.2021.2023644","article-title":"Search for potentially biased epidermal growth factor receptor (EGFR) inhibitors through pharmacophore modelling, molecular docking, and molecular dynamics (MD) simulation approaches","volume":"41","author":"Jethwa","year":"2023","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bioorg.2025.108991_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmgm.2020.107639","article-title":"Molecular dynamics, MM\/PBSA and in vitro validation of a novel quinazoline-based EGFR tyrosine kinase inhibitor identified using structure-based in silico screening","volume":"99","author":"Ornnork","year":"2020","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.bioorg.2025.108991_bb0210","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1021\/jm501929n","article-title":"Development of novel ACK1\/TNK2 inhibitors using a fragment-based approach","volume":"58","author":"Lawrence","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108991_bb0215","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1016\/j.bmc.2015.02.020","article-title":"SAR refinement of antileishmanial N2,N4-disubstituted quinazoline-2,4-diamines","volume":"23","author":"Zhu","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108991_bb0220","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1021\/acsinfecdis.0c00680","article-title":"A diverse range of Hemozoin inhibiting scaffolds act on plasmodium falciparum as Heme complexes","volume":"7","author":"Openshaw","year":"2021","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.bioorg.2025.108991_bb0225","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.bmcl.2018.11.043","article-title":"Design, synthesis and evaluation of N2,N4-diaminoquinazoline based inhibitors of phosphodiesterase type 5","volume":"29","author":"Pobsuk","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108991_bb0230","doi-asserted-by":"crossref","DOI":"10.3390\/app122110691","article-title":"Pharmacoinformatics analysis reveals flavonoids and Diterpenoids from Andrographis paniculata and Thespesia populnea to target hepatocellular carcinoma induced by hepatitis B virus","volume":"12","author":"Patil","year":"2022","journal-title":"Appl. Sci."},{"key":"10.1016\/j.bioorg.2025.108991_bb0235","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108991_bb0240","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.202301081","article-title":"Molecular docking, pharmacokinetic and molecular simulation analysis of novel mono-carbonyl curcumin analogs as L858R\/T790M\/C797S mutant EGFR inhibitors","volume":"20","author":"Bhandari","year":"2023","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.bioorg.2025.108991_bb0245","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2174\/0929867330666230309143711","article-title":"Structure-based virtual screening, molecular docking, molecular dynamics simulation, and metabolic reactivity studies of Quinazoline derivatives for their anti-EGFR activity against tumor angiogenesis","volume":"31","author":"Shah","year":"2024","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108991_bb0250","first-page":"3798","article-title":"Integrating network pharmacology and computational biology to propose Yiqi Sanjie formula's mechanisms in treating NSCLC: molecular docking, ADMET, and molecular dynamics simulation, Transl","volume":"13","author":"Wang","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108991_bb0255","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1080\/07391102.2023.2294179","article-title":"Lead optimization of Allium sativum L. compounds for PTP1B inhibition in diabetes treatment: in silico molecular docking and dynamics simulation","volume":"43","author":"Ojo","year":"2025","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bioorg.2025.108991_bb0260","doi-asserted-by":"crossref","first-page":"59","DOI":"10.14712\/fb2023069020059","article-title":"Correlation of short leukocyte telomeres and oxidative stress with the presence and severity of lung Cancer explored by principal component analysis","volume":"69","author":"Beli\u0107","year":"2023","journal-title":"Folia Biol. (Praha)."},{"key":"10.1016\/j.bioorg.2025.108991_bb0265","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12859-018-2093-6","article-title":"Prediction of sensitivity to gefitinib\/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis","volume":"19","author":"Zou","year":"2018","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.bioorg.2025.108991_bb0270","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1080\/07391102.2023.2213333","article-title":"Computational pharmacology profiling of borapetoside C against melanoma","volume":"42","author":"Bhattacharya","year":"2024","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bioorg.2025.108991_bb0275","doi-asserted-by":"crossref","first-page":"10616","DOI":"10.1073\/pnas.1221953110","article-title":"Effects of oncogenic mutations on the conformational free-energy landscape of EGFR kinase","volume":"110","author":"Sutto","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bioorg.2025.108991_bb0280","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1803152115","article-title":"Altered conformational landscape and dimerization dependency underpins the activation of EGFR by \u03b1 C\u2013 \u03b2 4 loop insertion mutations","volume":"115","author":"Ruan","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bioorg.2025.108991_bb0285","doi-asserted-by":"crossref","first-page":"118","DOI":"10.2174\/2589977511666190912154817","article-title":"In-silico design, ADMET screening, MM-GBSA binding free energy of some novel Isoxazole substituted 9-Anilinoacridines as HER2 inhibitors targeting breast Cancer","volume":"11","author":"Kalirajan","year":"2019","journal-title":"Curr. Drug Res. Rev."},{"key":"10.1016\/j.bioorg.2025.108991_bb0290","doi-asserted-by":"crossref","first-page":"5813","DOI":"10.1021\/acs.jpcb.0c03440","article-title":"Mechanistic study of potent fluorinated EGFR kinase inhibitors with a Quinazoline scaffold against L858R\/T790M\/C797S resistance mutation: unveiling the fluorine substituent cooperativity effect on the inhibitory activity","volume":"124","author":"Akher","year":"2020","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.bioorg.2025.108991_bb0295","doi-asserted-by":"crossref","first-page":"53848","DOI":"10.1074\/jbc.M403114200","article-title":"Epidermal growth factor receptor-deficient mice have delayed primary endochondral ossification because of defective osteoclast recruitment","volume":"279","author":"Wang","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2025.108991_bb0300","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non\u2013small-cell lung Cancer to Gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2025.108991_bb0305","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/10799893.2018.1557207","article-title":"Design and synthesis of novel 2,4-disubstituted aminopyrimidines: reversible non-covalent T790M EGFR inhibitors","volume":"38","author":"Patel","year":"2018","journal-title":"J. Recept. Signal Transduct."},{"key":"10.1016\/j.bioorg.2025.108991_bb0310","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3390\/nu17010181","article-title":"Development of a population pharmacokinetic model characterizing the tissue distribution of resveratrol after administration by different routes and doses in rats","volume":"17","author":"Cerqueira","year":"2025","journal-title":"Nutrients"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825008715?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825008715?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T11:59:38Z","timestamp":1777463978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825008715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":62,"alternative-id":["S0045206825008715"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108991","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quinazoline-based fourth-generation EGFR tyrosine kinase inhibitors to overcome C797S-mediated resistance in non-small cell lung Cancer (NSCLC)","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108991","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108991"}}